Albumin nanoparticles accumulate at tumors not only via passive targeting strategy due to their small particle size but also by an active targeting strategy mediated by albondin (gp-60) receptors that are overexpressed on tumor endothelial blood vessels [103] and by SPARC proteins that have a high affinity for albumin and are overexpressed on the cancer cell surface and at the tumor interstitium [12]. The gene discussed is SPARC; the disease is neoplasm.